Why Windtree Therapeutics Stock Is Soaring

Windtree Therapeutics WINT shares are surging on Wednesday after the company was granted U.S. patent number 11,583,540 titled "Istaroxime-Containing Intravenous Formulation For The Treatment Of Acute Heart Failure".

According to the USPTO, the patent covers intravenous infusion of istaroxime, or a metabolite of istaroxime, in human patients suffering from heart failure. Methods for extended infusion of istaroxime or its metabolites in individuals with heart failure are disclosed.

In particular, some methods disclosed include the infusion of istaroxime, or a metabolite thereof, for a period of time that is greater than six hours in order to improve cardiac relaxation without triggering arrhythmogenic events in an individual suffering from heart failure.

Other methods include administration of istaroxime until certain plasma concentration thresholds of istaroxime metabolites are achieved. Also disclosed are istaroxime metabolites with selective SERCA2a activation.

Windtree Therapeutics is a global, clinical-stage, biopharmaceutical and medical device company focused on the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets.

WINT Price Action: Windtree has a 52-week high of $1.43 and a 52-week low of $0.14.

Windtree shares are up 65.8% at $0.28 at the time of publication, according to Benzinga Pro.